Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
about
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experienceMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.The role of palliative chemotherapy in hospitalized patients.Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unitSurvival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experienceTriple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsClinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceParticipation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experiencePerceptions and referral trends into phase I oncology trials: results of a clinical surveyHigher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trialsPRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.Phase I trial outcomes in older patients with advanced solid tumoursPhase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumoursDose escalation methods in phase I cancer clinical trials.Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkersA study of motivations and expectations of patients seen in phase 1 oncology clinics.An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.The role of age on dose-limiting toxicities in phase I dose-escalation trials.Early oncology clinical trial design in the era of molecular-targeted agents.Moral justification of Phase 1 oncology trials.Risks and benefits of phase 1 clinical trial participation.Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.Early phase clinical trials: communicating the uncertainties of 'magnitude of benefit' and 'likelihood of benefit'.Further evidence of clinical benefit associated with participation in phase I oncology trials.Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
P2860
Q30665810-9A1F5ECC-D270-45ED-B951-2AFECB01B6B6Q33399986-7CD3E4CC-7262-4A0C-A554-8D780ACAEBF7Q33845387-867450A8-CE06-4881-966B-B93D8FD18E61Q33982668-4981C0AD-8B27-4DCD-9372-475B62668493Q34040965-0B4C7D19-D2D5-4E2B-9592-73987E8CF079Q34122784-A5289B04-5A5A-4383-9BB3-395F9E8E7FE9Q34252383-C343A1A1-5CC0-46A8-A807-EA72083BCE53Q34646376-343F7912-6A49-461D-9297-922A06DD27C3Q34781347-DD9FFA8E-936A-4181-9F6A-685F89775FD3Q34801461-F3D683D2-3E69-41DD-832F-BF49CBA3326BQ35104935-E31B68B4-EA0B-4353-9888-D91FD6A52D87Q35462692-2914F360-D89B-4C6C-B6DD-ACDFFC514571Q35584482-C9832E06-F279-4112-9A3A-61963293CFA1Q35770263-D56C2DC5-00DC-4EAD-B2B8-3F25C9BB7B8FQ35820055-761318F8-A226-4846-8198-670C56D98581Q36157118-ED119627-FAF4-4B33-B9C4-467FACDFADA6Q36288003-5A2C54C6-03B2-4D58-BCFA-AFE593A10A67Q36326389-EBAEDC7F-31F5-4C6A-8059-2D29B3B22B46Q36443880-CD957ED2-8452-48CA-8F0D-72456DB10497Q36547934-C1931B51-F733-41D5-89B3-B269972D6856Q36557802-90C9C3C7-28B8-42F7-B0BC-5A2C16783852Q37198192-8A34ADB4-F530-48CB-8F0D-A4DE15F94623Q37235500-D3DC4899-EDDB-4AC3-AE31-942CFB954ED8Q37417638-9E084104-A66B-437D-9BE6-4CA273DBADBCQ37444815-19DB249D-0897-4D46-B718-C8159BA9C3CCQ37552648-5A7DC99F-0D11-4A29-9ED5-2E872248E9E5Q37783623-E0BBD741-AA83-43BC-8FA7-254FDBEDEC00Q38210627-379CDF36-5AED-4A34-B934-487BDAC4177EQ38222465-CEB8B36C-1F61-4028-80D3-8DB7A83B0C01Q38735014-FB873F2B-4593-445E-978F-54E81A75CB2AQ38924049-839B87D4-7964-4818-A3B1-6AA8F9474889Q39442254-163B91D1-6A32-4EA1-BB0F-B3C812C446EBQ40025547-5B77DB9B-8F9F-4151-B1A8-440D5461CA03Q40368139-0D8A0C27-E837-419A-BC2B-7DD41DFA9CF5Q41161589-01633F07-0D1E-4A83-BB8A-684B9F117E48Q42749839-0F95AAB4-C13A-4A8D-B60F-F44C5C0F4F9EQ43088142-2CD28DBB-F024-4CDD-9671-B86E8C21E437Q43249390-183CDD0F-3B16-452C-A1F4-C7660EF52699Q43455943-1875BE28-E072-45F0-8DFF-70E69CB0A273Q43536539-FAAB97DC-B382-4685-A434-1A181E3A1C6B
P2860
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@ast
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@en
type
label
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@ast
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@en
prefLabel
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@ast
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@en
P2093
P2860
P356
P1476
Clinical outcome and prognosti ...... l Marsden Hospital experience.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604218
P407
P577
2008-03-18T00:00:00Z